Related Experiment Video
Updated: Aug 9, 2025

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
Coagulopathy is Initiated with Endothelial Dysfunction and Disrupted Fibrinolysis in Patients with COVID-19 Disease
Fatma Burcu Belen Apak1, Gulbahar Yuce2, Deniz Ilhan Topcu3
1Department of Pediatric Hematology and Oncology, Baskent University Medical Faculty, Sehit Temel Kuguoglu Street No 24, 06490 Bahcelievler/Ankara, Turkey.
Insights
COVID-19 coagulopathy involves distinct hemostatic changes, including endothelial dysfunction and impaired fibrinolysis. Early intervention with anticoagulation may improve outcomes and prevent ICU admission for severe cases.
Area of Science:
- Hematology
- Infectious Diseases
- Critical Care Medicine
Background:
- COVID-19 is associated with coagulopathy and thrombosis, but its pathogenesis remains unclear.
- Understanding hemostatic alterations is crucial for managing hospitalized patients.
Purpose of the Study:
- To evaluate hemostatic and inflammatory parameters in hospitalized COVID-19 patients.
- To determine if these parameters can differentiate between intensive care unit (ICU) and non-ICU patients.
Main Methods:
- Prospective case-control study of 51 hospitalized COVID-19 patients and 21 controls.
- Analysis of various hemostatic markers (e.g., fibrinogen, D-dimer, EPCR, TPA) and inflammatory markers at admission.
- Comparison of parameters between ICU and non-ICU groups, and survivors versus non-survivors.
Main Results:
- COVID-19 patients showed increased fibrinogen, PT, EPCR, D-dimer, selectins, PAI-1, and TPA, with decreased SFMC, PDMP, antithrombin, and protein C compared to controls.
- Tissue plasminogen activator (TPA) levels significantly differed between ICU and non-ICU patients.
- Findings suggest distinct coagulopathy with early endothelial involvement and fibrinolytic shutdown.
Conclusions:
- COVID-19 associated coagulopathy differs from sepsis-induced DIC.
- Early endothelial function restoration may prevent ICU progression.
- Consider early LMWH therapy for COVID-19 patients to improve endothelial function and anticoagulation, pending bleeding risk assessment.
Abstract:
A substantial group of patients suffer from Covid-19 (CAC) coagulopathy and are presented with thrombosis. The pathogenesis involved in CAC is not fully understood. We evaluated the hemostatic and inflammatory parameters of 51 hospitalized Covid-19 adult patients and 21 controls. The parameters analyzed were danger signal molecule (High molecular weight group box protein-1/HMGBP-1), platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT), D-dimer, fibrinogen, endothelial protein C receptor (EPCR), soluble E-selectin, soluble P-selectin, thrombomodulin, tissue plasminogen activator (TPA), plasminogen activator inhibitor-1 (PAI-1), soluble fibrin monomer complex (SFMC), platelet-derived microparticles (PDMP), β-thromboglobulin, antithrombin and protein C. The main objective of our study was to investigate which part of the hemostatic system was mostly affected at the admission of Covid-19 patients and whether these parameters could differentiate intensive care unit (ICU) and non-ICU patients. In this prospective case-control study, 51 patients ≥ 18 years who are hospitalized with the diagnosis of Covid-19 and 21 healthy control subjects were included. We divided the patients into two groups according to their medical progress, either in ICU or non-ICU group. Regarding the outcome, patients were again categorized as a survivor and non-survivor groups. Blood samples were collected from patients at admission at the time of hospitalization before the administration of any treatment for Covid-19. The analyzes of the study were made with the IBM SPSS V22 program. p < 0.05 was considered statistically significant. A total of 51 adult patients (F/M: 24/27) (13 ICU and 38 non-ICU) were included in the study cohort. The mean age of the patients was 68.1 ± 14.4 years. The control group consisted of 21 age and sex-matched healthy individuals. All of the patients were hospitalized. In a group of 13 patients, Covid-19 progressed to a severe form, and were hospitalized in ICU. We found out that the levels of fibrinogen, prothrombin time (PT), endothelial protein-C receptor (EPCR), D-dimer, soluble E-selectin, soluble P-selectin, plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (TPA) were increased; whereas, the levels of soluble fibrin monomer complex (SFMC), platelet-derived microparticles (PDMP), antithrombin and protein-C were decreased in Covid-19 patients compared to the control group at hospital admission. Tissue plasminogen activator was the only marker with a significantly different median level between ICU and non-ICU groups (p < 0.001). In accordance with the previous literature, we showed that Covid-19 associated coagulopathy is distinct from sepsis-induced DIC with prominent early endothelial involvement and fibrinolytic shut-down. Reconstruction of endothelial function at early stages of infection may protect patients from progressing to ICU hospitalization. We believe that after considering the patient's bleeding risk, early administration of LMWH therapy for Covid-19, even in an outpatient setting, may be helpful both for restoring endothelial function and anticoagulation. The intensity of anticoagulation in non-ICU and ICU Covid-19 patients should be clarified with further studies.
Supplementary Information:
The online version contains supplementary material available at 10.1007/s12291-023-01118-3.
Related Concept Videos
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Venous Thrombosis I: Introduction
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

